您的位置: 首页 > 农业专利 > 详情页

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
专利权人:
Acadia Pharmaceuticals Inc.
发明人:
David M. Weiner,Robert E. Davis,Mark R. Brann,Carl-Magnus A. Andersson,Allan K. Uldam
申请号:
US14086838
公开号:
US08921393B2
申请日:
2013.11.21
申请国别(地区):
US
年份:
2014
代理人:
摘要:
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充